Over a year annualised (CAGR), under a year absolute. Computed from AMFI's published
NAV history for this scheme.
Risk
Volatility
Sharpe
Sortino
Beta
Alpha
Max fall
R²
This scheme
16.2%
1.51
2.84
0.71
20.82%
-15.1%
46.16
Nifty 500 benchmark
15.2%
0.39
0.58
—
—
-37.3%
—
Risk-free rate 6.5%. Beta, alpha and R² are regressed on the
34 months this scheme and its benchmark share.
Growth of ₹100 since launch
Drawdown from peak (%)
Every one-year period it has lived through
Windows
Worst
Median
Best
Periods that lost money
471
0.5%
20.5%
65.0%
0%
Every one-year holding period in this scheme's history, not just the last one — the
spread a real investor would have met depending only on when they started.
How it behaves against its benchmark
Up capture
Down capture
Correlation
Tracking error
Information ratio
Treynor
126%
36%
0.68
12.7%
1.48
36.23
Up capture is how much of the benchmark's gain this scheme kept in the months the
benchmark rose; down capture, how much of its fall it took. Below 100 on the down side and above it
on the up side is the combination every fund is trying for and few reach.
Measured over the 34 months this scheme and
Nifty 500 share.
HDFC Pharma and Healthcare Fund
Regular Plan · Growth Option
Allocation
By asset
Equity
96.77%
Cash & Equivalents
3.23%
By market cap
Large Cap
27.89%
Mid Cap
33.16%
Small Cap
32.45%
Unclassified
4.92%
Concentration
Number of stocks
38
Top 5 stocks
30.15%
Top 10 stocks
47.76%
Top 20 stocks
74.95%
Lines in the filing
40
Largest holding
9.39%
Largest sector
Pharmaceuticals & Biotechnology 71.27%
Effective stocks
26.4
Sectors held
4
Cash
3.23%
Effective stocks is what the concentration works out to: a fund holding
38 names but most of its money in a few
behaves like a fund of 26. Cash includes repo and TREPS, which
every fund parks money in overnight.
Sector split
Pharmaceuticals & Biotechnology
71.27%
Healthcare Services
22.13%
Cash & Equivalents
3.23%
Healthcare Equipment & Supplies
2.36%
Retailing
1.01%
HDFC Pharma and Healthcare Fund
Regular Plan · Growth Option · holdings
Top 30 holdings
#
Company
Sector
Shares held
Value ₹ cr
% of fund
1
Divis Laboratories Ltd.
Pharmaceuticals & Biotechnology
353,687
329
9.39%
2
Sun Pharmaceutical Industries Ltd.
Pharmaceuticals & Biotechnology
1,595,093
290
8.28%
3
TREPS - Tri-party Repo
Unclassified
—
163
4.67%
4
Alkem Laboratories Ltd.
Pharmaceuticals & Biotechnology
314,859
163
4.64%
5
Cipla Ltd.
Pharmaceuticals & Biotechnology
1,080,050
145
4.15%
6
Apollo Hospitals Enterprise Ltd.
Healthcare Services
158,200
129
3.69%
7
Torrent Pharmaceuticals Ltd.
Pharmaceuticals & Biotechnology
266,486
128
3.65%
8
Max Healthcare Institute Limited
Healthcare Services
1,359,696
126
3.61%
9
Aster DM Quality Care Limited
Healthcare Services
1,786,027
125
3.56%
10
Lupin Ltd.
Pharmaceuticals & Biotechnology
611,505
124
3.55%
11
Neuland Laboratories Limited
Pharmaceuticals & Biotechnology
53,164
114
3.24%
12
Shilpa Medicare Ltd
Pharmaceuticals & Biotechnology
1,080,751
113
3.23%
13
Dr Reddys Laboratories Ltd.
Pharmaceuticals & Biotechnology
904,958
112
3.19%
14
Acutaas Chemicals Limited
Pharmaceuticals & Biotechnology
339,010
111
3.18%
15
Anthem Biosciences Limited
Pharmaceuticals & Biotechnology
1,291,629
111
3.17%
16
Ipca Laboratories Ltd.
Pharmaceuticals & Biotechnology
541,736
104
2.98%
17
Global Health Limited
Healthcare Services
698,170
95
2.72%
18
Rubicon Research Limited
Pharmaceuticals & Biotechnology
544,383
88
2.52%
19
Krishna Institute Of Medical Sciences Limited
Healthcare Services
984,676
74
2.10%
20
Glenmark Pharmaceuticals Ltd.
Pharmaceuticals & Biotechnology
312,887
73
2.09%
21
Molbio Diagnostics Limited
Healthcare Equipment & Supplies
538,006
70
2.01%
22
Vijaya Diagnostic Centre Limited
Healthcare Services
488,093
70
2.00%
23
Zydus Lifesciences Limited
Pharmaceuticals & Biotechnology
548,897
64
1.82%
24
Gland Pharma Ltd.
Pharmaceuticals & Biotechnology
214,955
62
1.78%
25
Wockhardt Ltd.
Pharmaceuticals & Biotechnology
283,279
60
1.71%
26
Jupiter Life Line Hospitals Limited
Healthcare Services
2,324,391
59
1.68%
27
Metropolis Healthcare Ltd.
Healthcare Services
1,081,488
59
1.67%
28
Sai Life Sciences Limited
Pharmaceuticals & Biotechnology
361,951
55
1.58%
29
Biocon Ltd.
Pharmaceuticals & Biotechnology
1,390,421
51
1.47%
30
SYMBIOTEC PHARMALAB LIMITED
Pharmaceuticals & Biotechnology
404,865
48
1.36%
HDFC Pharma and Healthcare Fund
Regular Plan · Growth Option · where the money sits
What the manager did last month
Between the filings of 30 Jun 2026 and 31 Jul 2026.
A position grows because the manager bought or because the price rose; only the share count separates them.
Bought
Sold
New positions
Sold out of
Price move of holdings
₹133 cr
₹0 cr
3
1
+3.52%
Stock
Shares traded
Shares
Price
Value ₹ cr
New position
Jupiter Life Line Hospitals Limited
2,175,025
entered
—
72.1
Torrent Pharmaceuticals Ltd.
131,000
entered
—
67.1
Apollo Hospitals Enterprise Ltd.
51,700
entered
—
46.3
Added to
Divis Laboratories Ltd.
49,600
+17.5%
+22.5%
40.0
Dr Reddys Laboratories Ltd.
291,958
+146.0%
-15.4%
33.5
Biocon Ltd.
657,177
+89.6%
+1.8%
28.0
Neuland Laboratories Limited
11,286
+27.4%
+2.5%
21.5
Sun Pharmaceutical Industries Ltd.
30,000
+2.2%
+6.9%
6.0
Global Health Limited
25,877
+4.2%
+7.0%
3.6
Sold out of
Jupiter Life Line Hospitals Limited
50,000
exited
—
7.1
Not equity
Previous filing
This filing
Change
Cash, repo and TREPS
₹0 cr
₹0 cr
+₹0 cr
The list above is stocks and fund units. Treasury bills, repo and money-market
lines roll over every month by design — they are not decisions, so they are totalled here rather
than listed as activity.
Not investment advice. InvestVerdict is not a SEBI-registered Investment
Adviser or Research Analyst. Every figure is computed from AMFI's published NAV history and the
portfolio the AMC filed with AMFI; none of it is a recommendation to buy, hold or sell. Past
returns do not predict future ones. Generated 28 Oct 2026.
